DARPin
Showing 1 - 14 of 14
Leukemia, Relapsed, Myeloid Trial in Netherlands, Switzerland (MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123
Recruiting
- Leukemia
- +3 more
- MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70)
-
Amsterdam, Netherlands
- +4 more
Jan 4, 2023
Advanced Malignant Solid Tumor Trial in France, Netherlands (MP0317, a tri-specific fibroblast activation protein (FAP) x CD40
Recruiting
- Advanced Malignant Solid Tumor
- MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate
-
Lyon, Cedex 08, France
- +3 more
Nov 4, 2022
EGFR-mutated NSCLC (Disorder) Trial in United States (MP0250 DARPin® drug candidate, Osimertinib)
Terminated
- EGFR-mutated NSCLC (Disorder)
- MP0250 DARPin® drug candidate, Osimertinib
-
Scottsdale, Arizona
- +9 more
May 27, 2020
Breast Cancer Female Trial in Tomsk (99mTc-ADAPT6, 99mTc-DARPinG3)
Recruiting
- Breast Cancer Female
-
Tomsk, Russian FederationTomsk NRMC
May 12, 2022
Multiple Myeloma in Relapse Trial in Worldwide (MP0250 plus BOR+DEX)
Completed
- Multiple Myeloma in Relapse
- MP0250 plus BOR+DEX
-
Wien, Vienna, Austria
- +23 more
Aug 19, 2021
Advanced Solid Tumor Trial in Lyon, Toulouse, Villejuif (MP0310 (AMG 506))
Recruiting
- Advanced Solid Tumor
- MP0310 (AMG 506)
-
Lyon, France
- +2 more
Dec 21, 2021
Molecular Imaging in HER2-positive Breast Cancer During
Enrolling by invitation
- HER2-positive Breast Cancer
- Female
-
Tomsk, Russian Federation
- +1 more
Jun 7, 2022
